1051 related articles for article (PubMed ID: 24824495)
1. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
2. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
[TBL] [Abstract][Full Text] [Related]
4. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
5. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
[TBL] [Abstract][Full Text] [Related]
7. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
[TBL] [Abstract][Full Text] [Related]
9. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
[TBL] [Abstract][Full Text] [Related]
10. Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
Xu YJ; Zheng H; Gao W; Jiang GN; Xie HK; Chen C; Fei K
Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):887-93. PubMed ID: 25156899
[TBL] [Abstract][Full Text] [Related]
11. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
[TBL] [Abstract][Full Text] [Related]
14. Do tumours located in the left lower lobe have worse outcomes in lymph node-positive non-small cell lung cancer than tumours in other lobes?
Kudo Y; Saji H; Shimada Y; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N
Eur J Cardiothorac Surg; 2012 Sep; 42(3):414-9. PubMed ID: 22398463
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
[TBL] [Abstract][Full Text] [Related]
17. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer.
Nentwich MF; Bohn BA; Uzunoglu FG; Reeh M; Quaas A; Grob TJ; Perez D; Kutup A; Bockhorn M; Izbicki JR; Vashist YK
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):781-7. PubMed ID: 23778087
[TBL] [Abstract][Full Text] [Related]
18. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
Cohen C; Pop D; Venissac N; Poudenx M; Otto J; Castelnau O; Mouroux J
Thorac Cardiovasc Surg; 2018 Mar; 66(2):129-134. PubMed ID: 28992652
[TBL] [Abstract][Full Text] [Related]
20. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]